Skip to content
Catalyst

PapersPMID:32134758

Randomized trial of intracoronary adenosine as adjunctive therapy for prevention of the no-reflow phenomenon.

Coronary artery disease2020The record ↗

findings
3
compound
1
endpoints
3
PMID:32134758
  1. Finding, very limited evidenceno difference foundLeft ventricular ejection fraction
  2. Finding, very limited evidenceno difference foundHospital length of stay
  3. Finding, very limited evidenceno difference foundAll-cause mortality
Study, every finding
RCT
Dose studied, every finding
two intracoronary bolus doses, before and after stenting; amount not stated in the abstract

No finding here moved its endpoint.

  • “Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups.”
    • Population
      Patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention; intracoronary adenosine versus intracoronary normal saline
    • Population
      Patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention; intracoronary adenosine versus intracoronary normal saline
    • Duration
      4 weeks
      Population
      Patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention; intracoronary adenosine versus intracoronary normal saline; 30-day horizon

Study record

Design
randomised controlled trial
Species
human
Population
patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
Participants
104
Comparator
placebo
Duration
not reported
Endpoints measured
6